Ten world-leading scientists and clinicians will join an Australian contingent to showcase innovations in medical imaging; the impact on healthcare and how multi-disciplinary collaborations are taking this innovation into the clinic.
Presentations will feature imaging technologies and techniques emerging from academic and clinical research to provide a better platform for the diagnosis, monitoring and treatment of cancer; cardiovascular problems; neurological diseases and disorders; mental health issues; and spinal trauma. Imaging@Brisbane will also explore the latest developments in radiotherapy and theranostics.
There will be a lunch-time debate titled ‘Finders Keepers: Who owns and who stores clinical imaging data for research’.
The Conference will wrap up with site visits to world-class imaging facilities including The University of Queensland Centre for Advanced Imaging; Herston Imaging Research Facility and the Translational Research Institute Innovation and Translation Centre in collaboration with Siemens Healthineers, with the aim of forming future collaborations and partnerships.
12 RANZCR CPD points can be claimed for attendance at Imaging@Brisbane 2018.
Andreas Adam is Professor of Interventional Radiology at the University of London.
He trained in medicine at the Middlesex Hospital Medical School, and specialised in radiology at the Royal Postgraduate Medical School, and is a Fellow of the Royal College of Radiologists, the Royal College of Physicians and the Royal College of Surgeons. In 1992 he was appointed to the first professorial chair of interventional radiology in Europe, at King’s College London. In 2012 -2015 he served as Dean of the first state medical school in Cyprus.
His research work has shaped clinical practice internationally and has been recognised by the award of Fellowship of the Academy of Medical Sciences. He has made extensive original contributions to the medical and scientific literature, has published eleven books, and has served as Editor-in-Chief of Cardiovascular and Interventional Radiology.
Professor Adam was one of the architects of the European Society of Radiology, which he helped to create by merging the European Congress of Radiology with the European Association of Radiology. He has held the presidencies of eight national and international societies, including the Royal College of Radiologists and the European Society of Radiology.
He has received numerous honours and awards, including fifteen eponymous lectures, Honorary Fellowship of seventeen national radiological societies, five gold medals and two Honorary Doctorates. In 2012 he was made a Commander of the Most Excellent Order of the British Empire in recognition of his contributions to interventional radiology.
Prof. Ahmadzadehfar received his medical degree from Guilan Medical University in Iran 1999 and did his residency in Nuclear Medicine in Germany at the Department of Nuclear Medicine, University Hospital Bonn 2003-2008. From 2008 to 2013 he was the assistant medical director of the Department of Nuclear Medicine University Hospital Bonn and from 2013 works as the head of the therapy section. 2013-2015 he studied medical technique at the university hospital Bonn and received his MSc. Prof. Ahmadzadehfar serves as an editor and reviewer for several international journals and has authored and coauthored over 120 papers and book chapters. His main research area is targeted radionuclide therapy and Theranostics (like radionuclide therapy of NEN using PRRT, radioemboliazion of liver tumors and radioligand therapy of metastatic prostate cancer using Lu-PSMA).
Dr. Ellingson is an Associate Professor of Radiology, Biomedical Physics, Psychiatry and Bioengineering at UCLA in the Departments of Radiology, Psychiatry, and Biobehavioral Sciences. Dr. Ellingson is the Director of the UCLA Brain Tumor Imaging Laboratory (BTIL) and Co-Director of the Center for Computer Vision and Imaging Biomarkers (CVIB). Dr. Ellingson possess a broad background in biomedical engineering, mathematics, quantum physics, molecular imaging, bioelectronics, and medical instrumentation. Dr. Ellingson's research focuses on the development, testing, validation, and implementation of advanced MR and PET imaging biomarkers for brain pathology and therapeutic response evaluation in human clinical trials. Dr. Ellingson serves as the principal investigator or chair of the imaging core in many industry and government-funded clinical trials, serves on many steering committees and holds many advisory roles related to neuro-oncology neuroimaging and has co-authored more than 100 peer-reviewed original research articles relating to neuroimaging.
Jim completed his PhD at the University of Queensland, Australia (UQ) in 2007 and a post-doctoral fellowship (2010) also at UQ (CCRE-Spine). His multidisciplinary teams' contributions to the field range from the identification of novel magnetic resonance imaging markers to quantify alterations in spinal cord anatomy and skeletal muscle degeneration as potential markers of poor functional recovery following head/neck trauma to leading large multidisciplinary studies investigating the neurobiological mechanisms of persistent spinal pain (generally) and head/neck trauma (e.g. whiplash injury) following a motor vehicle collision (specifically). He is currently a Professor of Allied Health in the Faculty of Health Sciences at the University of Sydney and the Northern Sydney Local Health District. Prior to this, Jim was a tenure-track Associate Professor in the Feinberg School of Medicine at Northwestern University in Chicago, USA, where he remains an adjunct Professor and Principal Investigator of the Neuromuscular Imaging Research Laboratory. Jim is passionate about mentoring the next generation of health, medical, and engineering researchers. His dedication to supervising students and post-doctoral fellows earned him recognition as the 2015 recipient of the Faculty Award for Engagement and the 2017 Ver Steeg Faculty Award for Excellence in working with Graduate Students from the Graduate School of Northwestern University. His collaborative work with clinicians, other researchers, and students from around the world aims to pioneer new scientific knowledge, diagnostics, and objective measures to inform and test new therapies towards permitting millions of patients with acute and chronic spinal pain to live a healthy, active life.
Dr. Frangou, MD, PhD, FRCPsych serves as Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York (http://www.frangougroup.org). Previously, Dr. Frangou led the Section of the Neurobiology of Psychosis at the Institute of Psychiatry, King's College London (KCL), UK. She received her PhD at KCL and completed her psychiatry training at the Maudsley Hospital, UK. Her work has greatly advanced the understanding of the pathophysiology of schizophrenia and bipolar disorder, particularly in relation to genetic and familial risk. She has made groundbreaking contributions to the characterization of brain mechanisms of "resilience" in those at high familial risk for psychosis. She has authored more than 200 highly cited papers and has written or contributed to ten books on mental illness. In 2016, she published "Women in Academic Psychiatry: A Mind to Succeed" to promote women psychiatrists aiming for academic leadership positions.
Dr. Frangou is a fellow of the European Psychiatric Association (EPA), the Royal College of Psychiatrists and the American Psychiatric Association. She is the founding chair of the Neuroimaging Section of the EPA and the Neuroimaging Network of the European College of Neuropsychopharmacology. She co-chairs the Lifespan Working Group of the Enhancing NeuroImaging Genetics Through Meta-Analysis (ENIGMA) consortium and the consortium for the investigation of Psychopathology and Allostatic Load Across the Lifespan (PALS). She is editor for European Psychiatry and Human Brain Mapping and member of the editorial board of major scientific journals.
Dr. Fuller is a 2017 Sabin Family Foundation Fellow, as well as an Assistant Professor and Associate Director of MRI within the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center. After his completing medical school and PhD training in Radiological Sciences (Human Imaging) at the University of Texas Health Science Center at San Antonio, Dr. Fuller joined MD Anderson in 2011, becoming a board-certified radiation oncologist in the Head and Neck Section, with subsequent subspecialty certification in Clinical Informatics. His research focus is in the development of evidence-based "precision radiotherapy" techniques by incorporation of novel MRI methodologies for normal tissue and tumor, leveraging innovative imaging informatics approaches to improve patient care through technology development.
Stuart Michael Grieve (SMG) is a clinician/scientist with a career focus on applying non-invasive imaging in healthcare and achieving fundamental advances in basic imaging science such as new imaging or image processing technologies. He is the Parker Hughes Professor of Radiology at the University of Sydney (USYD) and also a radiologist at Royal Prince Alfred Hospital (RPAH). He was primarily a neuroimaging researcher until 2013, when he switched to a focus on both, cardiovascular and brain. His laboratory is at the Charles Perkins Centre (USYD) where his team pursues a research program that extends from basic imaging science, post-processing, basic physiology of the cardiovascular system and brain to clinical translational studies that aim to directly alter practice. The major focus of his research is the quantitative analysis imaging data, especially direct measures of neurological, blood flow and myocardial function using MRI.
Professor Hammers has been Head of the King's College London & Guy's and St Thomas' PET Centre since 2013. He is Professor of Imaging and Neuroscience and Interim Head (with René Botnar) of the School of Biomedical Engineering and Imaging Sciences. He trained in medicine and then in Neurology in Germany, France, and the UK. He obtained an MD in MR imaging of the hippocampus, and a PhD in PET investigations in focal epilepsy, before leading his own group at the Medical Research Council's Clinical Sciences Centre at Hammersmith Hospital, creating the Hammers_mith brain atlases. As Chair of Excellence in Functional Neuroimaging at the Neurodis Foundation in Lyon, France, 2009-2014, he wrote several of the grants that established France's first simultaneous PET-MR, before joining King's.
He is affiliated with several professional organisations, has won several distinctions, is an acclaimed teacher, and reviews frequently for numerous journals and grant-giving bodies. He is an author on about 200 articles, proceedings, and chapters (h index Web of Science 42, Google Scholar 50).
His research areas are functional imaging with PET to understand mechanisms of neurological disease, and structural neuroimaging using MRI and anatomical segmentation using the large manually annotated Hammers_mith brain atlas database. Both the PET and MR research are applied to the epilepsies and neurodegenerative diseases. The ultimate goal is to benefit individual patients through the clinical application of neuroscience, e.g. through classification and decision support with machine-learning techniques. In addition, methodological work is underpinning all applications, particularly for simultaneous PET-MR.
Colin Masters has focused his career on research in Alzheimer's disease and other neurodegenerative diseases, including Creutzfeldt-Jakob disease. His work over the last 35 years is widely acknowledged as having had a major influence on Alzheimer’s disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the Aβ amyloid protein which causes Alzheimer’s disease. This work has led to the continued development of diagnostics and therapeutic strategies. More recently, his focus has been on describing the natural history of Alzheimer’s disease as a necessary preparatory step for therapeutic disease modification. Professor Masters is currently the Head of the Neurodegeneration Division, Florey Institute and a Laureate Professor at the University of Melbourne. He is also a consultant at the Royal Melbourne Hospital. His achievements have been recognised by the receipt of many international awards.
Professor Reza Razavi is Vice President & Vice-Principal of Research at King’s College, London, and Director of Research at King’s Health Partners. He is Professor of Paediatric Cardiovascular Science at King’s College, London and Consultant Cardiologist at Guy’s and St Thomas’ NHS Foundation Trust, and his previous roles include Head of the School of Biomedical Engineering & Imaging Sciences, leading this research centre in its 10 year transformation from 20 to over 400 active researchers. He is also Director of the Wellcome Trust/ EPSRC Medical Engineering Centre for Research Excellence, one of 4 such centres within the U.K., with a strong focus on imaging technologies, and his own research is in imaging and biomedical engineering related to cardiovascular disease.
One key area of focus is cardiac MRI in relation to congenital heart disease, electrophysiology and heart failure, image guided intervention, XMR (X-ray and MRI) guided cardiac catheterisation and methodological advances to move to faster 3-Dimensional cardiac imaging. He has substantial grant income, and extensive experience working with industry to deliver technologies that move into clinical products, and has published widely in high impact journals with over 200 journal publications. He actively participates in both national and international bodies in the fields of cardiovascular imaging, including Chair of the British Society for Cardiovascular MRI and the organisation of national and international societal meetings, and includes developing curriculum for the training of doctors in this specific area.
Earned medical degree in 1979. After completing residencies and fellowship, attended Graduate School of Medicine at Kyoto University and got Ph.D. degree in 1987. During this period, mostly involved in the very early studies of body MR imaging especially in gynaecologic field, and published several articles including the one entitled "Uterine cervical cancer: assessment with high-field MR imaging" published in Radiology 1986. From that time, working as one of pioneers of gynaecologic MRI research for over 30 years, and published several books and over 400 articles in peer-reviewed journals in English. Starting with radiological-pathological correlation for cancer imaging, recent areas of interest are functional body MRI including cine MR to evaluate uterine functions, diffusion-weighted images in oncology, diffusion tensor imaging of the uterus, etc. After appointed to a professor and chairperson, dedicated to encouraging junior faculties to get interested in academic activities. A string of awards in the annual meetings of Radiological Society of North America (RSNA), European Congress of Radiology (ECR), and International Society for Magnetic Resonance in Medicine (ISMRM), Society of Nuclear Medicine etc. are all the fruits of this devotion. Honours include Honorary Membership of the ECR in 2007, Fellow of ISMRM in 2012, and the Honorary Member of RSNA in 2014.
Brodtmann is the only stroke and cognitive neurologist in Australia, expert in the diagnosis and management of cognitive disorders. In 2015 she was a recipient of a Dementia Research Team Grant as CIA, leading an international group of 10 CIs and 4 AIs, and 2016 awardee of a Heart Foundation Future Leader Fellowship. She is director of 3 cognitive services in Melbourne: Eastern Cognitive Disorders Clinic, Austin Health Neurology, and Royal Melbourne Hospital. She is Co-Head of the Dementia Theme at the Florey and newly appointed Deputy Director of the Melbourne Dementia Research Centre. Quals: PhD University of Melbourne (2001-2004); Fellow of the Royal Australian College of Physicians (1999); MBBS University of Melbourne (1987-1992)
Peter Greer completed his MSc in medical physics in New Zealand and his PhD at the University of Adelaide, Australia in 2001. He has worked as a radiation oncology medical physicist in New Zealand, Canada and Australia. He currently leads medical physics research at Calvary Mater Newcastle and University of Newcastle. His major areas of research and development interest are treatment verification with imaging and MRI in RT.
Professor Michael Hofman is a nuclear medicine physician at the Centre for Molecular Imaging, Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia's only public hospital dedicated to cancer treatment, research and education. He has a co-appointment at the Univeristy of Melbourne and previously completed a fellowship at Guy's & St Thomas' hospital in London. He has particular interest in novel F-18 and Ga-68 PET radiotracers, and theranostic applications. This interest began with Ga-68/Lu-177 imaging and therapy for neuroendocrine tumours and has progressed to a primary interest in prostate cancer. He is the principal investigator of the “proPSMA Study”, a 10-site randomised trial of PSMA PET for staging high risk prostate cancer. He recently published the first prospective data on Lu-177-PSMA and is chair of the “TheraP Study”, a multi-centre randomised trial of Lu-177-PSMA versus cabazitaxel chemotherapy. He has authored over 100 peer-reviewed articles and several book chapters. He serves as a scientific member for the Australasian Radiopharmaceutical Trials Network (ARTnet) and an associate editor for several journals including Cancer Imaging, Leukaemia & Lymphoma, and the Journal of Medical Imaging and Radiation Oncology (JMIRO).
Professor Michael Schuetz is a practicing orthopaedic surgeon and research leader in the field of trauma care and orthopaedic trauma research. Since April 2016 he holds the position of Chair for Trauma- and Reconstructive Surgery at the Humboldt & Free University of Berlin as well is the Director of the Centre for musculoskeletal Surgery at the Charité Hospital in Berlin. From 2004 until 2016 Michael Schuetz was the Chair of Trauma at the Queensland University of Technology (QUT) as well as Director of Trauma at the Princess Alexandra Hospital and remains Adjunct Professor at QUT.Professor Schuetz’s research interests lie in the fields of orthopaedic trauma surgery, trauma system management, fracture healing, regenerative medicine and implant development. He has published more then 200 peer-reviewed publications in high impact international journals including The lancet, Critical Care, Acta biomaterialia, Biomaterials and Science Translational Medicine. Michael has attracted over $8.5 million in funding to support his research from national and international granting organizations, including four Australian Research Council (ARC) Linkage Project Grants, one ARC Discovery Grant, one National Health and Medical Research Council (NHMRC) Development Grant and one National and International Research Alliances Program Grant from the Queensland Government.
Professor Graeme Jackson is Senior Deputy Director of The Florey Institute of Neuroscience & Mental Health, a Neurologist at the Austin hospital, Melbourne Australia, and a clinician researcher in advanced brain imaging and epilepsy. His research is based on using innovations in MRI technology to understand the structure and function of the brain, and applying that to the understanding of epilepsy. His focus is on translating research insights to the treatment of patients. He is also a Professorial Fellow of the University of Melbourne and Clinical Research Fellow of the National Health and Medical Research Council of Australia (NHMRC). He has received the NHMRC excellence award for highest ranked clinical fellow and, with other chief investigators, the NHMRC excellence award for highest ranked research program of the NHMRC and the Javitz award of the NIH (USA). He chairs the Science Council of Neuroscience Victoria and the Academic Board of the Institute for Social Neuroscience. He has served a term as Associate Editor of Epilepsia (Imaging) and is currently on the Diagnostic Methods commission of the International League against Epilepsy. He was awarded the 2016 Epilepsy Research Recognition Award for Clinical Science.
Gemma Figtree is a Professor in Medicine at the University of Sydney, and Research Lead for Cardiothoracic and Vascular Health at the Kolling Institute and for Northern Sydney Local Health District. She co-leads the Cardiovascular Theme for Sydney Health Partners, a NHMRC Advanced Health Research and Translation Centre and is the Chair of the University of Sydney’s multi-disciplinary Cardiovascular Initiative. Gemma completed her DPhil at Oxford University in 2002 supported by a Rhodes Scholarship and has continued in the field of oxidative signalling. She is committed to improving the care for heart attack patients by using her knowledge of redox signalling and molecular biology to develop methods of identifying those at highest risk of adverse outcome, and discovering novel therapies to prevent and treat events, inspired by her clinical work as an interventional cardiologist. Discoveries in her Laboratory have been published in leading journals Circulation, European Heart Journal, and FRBM, with >130 publications. Gemma is a principal investigator on grants >$6.5 mill. Having recently completed a co-funded NHMRC CDF and Heart Foundation Future Leader Fellowship, she has been awarded a Practitioner Fellowship. She is committed to the advancement of her field, and serves as a member of the Editorial Board of leading international cardiovascular journals Circulation and Cardiovascular Research, as well as being a founding editorial board member for Redox Biology, and an Associate Editor for Heart, Lung and Circulation. Her research and clinical perspective and leadership are recognised by her membership of the Scientific Board of Cardiac Society of Australia and New Zealand (responsible for International Relations), and her appointment to the Expert Advisory Panel for NHMRC Structural Review of Grants Program (2016-17), as well as the Clinical Issues Committee of the Heart Foundation. She is committed to the promotion and advocacy of cardiovascular research and has been recently appointed as President of the Australian Cardiovascular Alliance. She is a graduate of the Australian Institute of Company Directors, and serves/has served as a non-executive Director on multiple community Boards.
Paul Keall is a Professor in the Sydney Medical School, an NHMRC Senior Principal Research Fellow and the Director of the ACRF Image X Institute at the University of Sydney. His team of scientists, clinical partners and international collaborators create, share and apply novel cancer imaging and targeted radiotherapy methods. Several of these innovations have been translated to clinical practice for improved health care. Since being awarded his Ph.D. in 1996 he has risen to be in top tier of cancer imaging and radiotherapy researchers internationally. He was the Director of the Radiation Physics Division at Stanford University (2006-2010) where he was charged with leading the academic, clinical and educational missions of 70 academic and clinical staff. In 2010 he was awarded the prestigious Australia Fellowship and recruited to the University of Sydney. 3Outputs from his research include multiple bench-to-bedside clinical trials, 280 scientific publications, 20 patents, 8 licenses and three start-up companies. His work is funded primarily by competitive government research grants and he works closely with industry to apply his research output, and has 25 current and completed industrial research agreements. He is a chief investigator on the Australian MRI-Linac program. This collaboration between Australian and overseas universities has been funded by two NHMRC Program grants.
Caroline Rae received her PhD in NMR and metabolic control in 1993 from The University of Sydney. As an Oxford Nuffield Medical Fellow she spent four years at Oxford University in the MRC Biochemical and Clinical Magnetic Resonance Unit where she pioneered the use of magnetic resonance spectroscopy as a tool in multidisciplinary research into cognitive disorders. On her return to Australia she held several competitive Fellowships, including from the National Health and Medical Research Council before becoming Professor of Brain Sciences at The University of New South Wales and Director (research) at NeuRA Imaging; the first truly open access 3T Research MRI in Australia. Her current research is focused on the biochemical basis of brain function. Prof Rae is an Associate Editor for Neurochemical Research, Neurochemistry International and a member of the Editorial Board of Magnetic Resonance in Medicine. Awards include the 2017 Medal of the Australian and New Zealand Society for Magnetic Resonance.
Arnold Ng is associate professor at the department of Cardiology, Princess Alexandra Hospital, The University of Queensland, and visiting associate professor at The University of New South Wales. He has co-authored numerous scientific articles and his main research interests include multimodality imaging in heart failure, stable coronary artery disease, valvular heart disease and metabolic heart disease.
Dr. Guo received a B.Sc in Biological Sciences from Peking University and a Ph.D. in Neuroscience from the Stanford University, School of Medicine, followed by postdoctoral training at the Memory and Aging Center (UCSF). She is now a Team Head at the Mental Health Program at QIMR Berghofer. She has broad research experience, from molecular biology and genetics to electrophysiology and systems neuroscience. Her work focuses on understanding selective vulnerability at the network level in health and in neurodegenerative diseases, using modern neuroimaging techniques. She is also developing novel neuroimaging paradigms using naturalistic stimuli to understand the body-brain interaction and its breakdown in neurological and psychiatric disorders.
In addition he is Assistant Director of Specialised PET Services Queensland, based at the Royal Brisbane and Women’s Hospital. He is a consultant nuclear medicine physician and PET specialist who undertook fellowship training at the Mayo Clinic in Rochester, Minnesota and PET training at the Clinical PET Centre at St Thomas’ Hospital in London. He oversees the radiopharmacy laboratory at Royal Brisbane and Women’s Hospital which manufactures specialty PET tracers for supply to HIRF. Paul is the Vice President of the Australasian Association of Nuclear Medicine Specialists and a member of the Training Site Accreditation Committee for Nuclear Medicine in Australia. Paul has a variety of research interests in PET/CT and PET/MR including PSMA PET/CT and PET/MR in prostate cancer staging and radiotherapy planning, PSMA PET in renal cell carcinoma, hypoxia and FDOPA imaging of glioma, chemokine imaging and risk stratification in a variety of malignancies, and technical projects concerning motion correction and using kinetic analysis to improve the accuracy for detection of metastases.
Assoc. Prof. Kristofer Thurecht graduated from the University of Queensland, Australia, in 2005 with a PhD in polymer chemistry. In 2007, Assoc. Prof. Thurecht was simultaneously awarded a Ramsay Centenary Fellowship and 1851 Research Fellowship in the UK, and has since held both an ARC Australian Postdoctoral Fellowship (2008) and an ARC Future Fellowship (2012). In 2015 Assoc. Prof. Thurecht was awarded the RACI David Sangster Polymer Science and Technology Award from the Polymer Division. Assoc. Prof. Thurecht is currently a group leader within the Centre for Advanced Imaging (CAI) and the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland where he holds an NHMRC Career Development Fellowship (CDF2). His research focusses on the development of polymer and nanoparticle-based devices for nanomedicine. His team works across the boundaries of chemistry and materials, biology and imaging science to probe how nanomaterial properties affect their function in living animals. He is a CI in the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and CI/theme leader in the ARC Training Centre for Innovation in Biomedical Imaging and Technology.
Imaging@Brisbane 2018 is hosted by seven major research centres involved across three significant multi-modal medical imaging facilities located in the state's capital. This unique multi-disciplinary collaboration forges the foundation for a conference that will attract world-wide attendance and showcase all that medical imaging innovation has to offer health care now, and into the future.©Imaging@Brisbane 2018